Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience

Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.

[1]  J. Augsburger,et al.  Adjunctive techniques for optimization of ocular hemodynamics in children undergoing ophthalmic artery infusion chemotherapy , 2014, Journal of NeuroInterventional Surgery.

[2]  T. Merchant,et al.  Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation , 2014, Journal of pediatric hematology/oncology.

[3]  C. Shields,et al.  Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. , 2014, Ophthalmology.

[4]  C. Camargo,et al.  Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. , 2014, The journal of allergy and clinical immunology. In practice.

[5]  R. Khanna,et al.  Management and outcome of retinoblastoma with vitreous seeds. , 2014, Ophthalmology (Rochester, Minn.).

[6]  S. Brodie,et al.  Electroretinogram Monitoring of Dose-Dependent Toxicity after Ophthalmic Artery Chemosurgery in Retinoblastoma Eyes: Six Year Review , 2014, PloS one.

[7]  D. Abramson.  Retinoblastoma: saving life with vision. , 2014, Annual review of medicine.

[8]  S. Hetts,et al.  Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution , 2013, Clinical ophthalmology.

[9]  R. Jubran,et al.  Long‐term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low‐dose IMRT salvage , 2013, Pediatric blood & cancer.

[10]  C. Shields,et al.  Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. , 2012, Journal of neurosurgery. Pediatrics.

[11]  S. Brodie,et al.  Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results , 2012, British Journal of Ophthalmology.

[12]  D. Abramson,et al.  Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. , 2012, Investigative ophthalmology & visual science.

[13]  D. Abramson.  Chemosurgery for retinoblastoma: what we know after 5 years. , 2011, Archives of ophthalmology.

[14]  S. Brodie,et al.  Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results , 2011, British Journal of Ophthalmology.

[15]  S. Brodie,et al.  Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. , 2011, Archives of ophthalmology.

[16]  S. Brodie,et al.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. , 2008, Ophthalmology.

[17]  A. LinnMurphree.  Intraocular retinoblastoma: the case for a new group classification. , 2005 .

[18]  A. Linn Murphree.  Intraocular retinoblastoma: the case for a new group classification. , 2005, Ophthalmology clinics of North America.

[19]  C. Shields,et al.  Chemoreduction for unilateral retinoblastoma. , 2002, Archives of ophthalmology.